China Everbright Limited 0165
HKEX · Hong Kong SAR China · Finance
HKD 6.35+0.03 (+0.47%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
This article first appeared on GuruFocus. China Everbright Ltd (CEVIF) recently announced a total dividend of $0.01 per share, with the ex-dividend date set for 2026-09-16. For investors holding the stock, the ex-dividend date is a critical marker: shareholders must own shares before this date to qualify for the payment.
Why China Everbright stock is back in focus China Everbright (SEHK:165) has drawn fresh attention after the company guided for a 70% to 80% drop in first half 2026 profit attributable to shareholders compared with HK$399 million a year earlier. See our latest analysis for China Everbright. The earnings warning comes after a period where China Everbright’s share price has been under pressure, with the year to date share price return down 35.95% and the 1 year total shareholder return down...
Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, today announced the successful closing of a new financing round exceeding $31 million (over RMB 200 million).
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.